Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CB-NK-TGF-betaR2 + NR3C1
- Development stage
- Phase 1
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intratumoral
01
Overview
CB-NK-TGF-betaR2 + NR3C1 is an investigational cell therapy product consisting of allogeneic (donor-derived) natural killer (NK) cells, expanded from cord blood and genetically engineered to lack the TGF-beta receptor 2 (TGF-betaR2) and glucocorticoid receptor (NR3C1) genes. The deletion of TGF-betaR2 and NR3C1 is achieved via gene editing (such as CRISPR/Cas) to enhance the NK cells’ resistance to the immunosuppressive effects of transforming growth factor-beta and glucocorticoids present in the tumor microenvironment, particularly in glioblastoma. By preventing negative regulation by these pathways, the edited NK cells are intended to exert more potent anti-tumor activity. The product is under phase I clinical investigation primarily as an intratumoral immunotherapy in recurrent glioblastoma[1][2][6][7][9].
- Other names
- CB-NK-TGF-betaR2-/NR3C1-CB-NK-TGF-betaR2 and NR3C1 knockout NK cellsCB-NK-TGF-betaR-2 and NR3C1 knockout NK cellsCB-NK-TGF-betaR 2 and NR3C1 knockout NK cellsCord blood-derived expanded allogeneic natural killer cells with TGF-betaR2 and NR3C1 knockout
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on CB-NK-TGF-betaR2 + NR3C1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CB-NK-TGF-betaR2 + NR3C1.